Subscribe to RSS
DOI: 10.1055/s-2004-817975
J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York
Inhibition of HMG-CoA Reductase with Cerivastatin Lowers Dense Low Density Lipoproteins in Patients with Elevated Fasting Glucose, Impaired Glucose Tolerance and Type 2 Diabetes Mellitus
Publication History
Received: May 7, 2003
First decision: August 18, 2003
Accepted: October 30, 2003
Publication Date:
14 May 2004 (online)
![](https://www.thieme-connect.de/media/eced/200405/lookinside/thumbnails/10.1055-s-2004-817975-1.jpg)
Abstract
Objective: While 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors effectively decrease LDL cholesterol, it remains controversial whether these agents also lower dense LDL, which are considered particularly atherogenic.
Methods: We examined the effects of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor cerivastatin on lipids, lipoproteins, and apolipoproteins in 69 patients with elevated fasting glucose, impaired glucose tolerance, or type 2 diabetes, combined hyperlipoproteinemia and increased concentrations of dense LDL (apo B in LDL-5 plus LDL-6 > 25 mg/dl). The study was a multicenter, double-blind, randomized, parallel-group comparison of cerivastatin at 0.4 mg daily for 12 weeks (n = 34) and placebo (n = 35).
Results: Cerivastatin significantly reduced cholesterol (- 20 %, p < 0.001), IDL cholesterol - 37 %, p < 0.001), LDL cholesterol (- 26 %, p < 0.001), apolipoprotein B (- 25 %, p < 0.001), triglycerides (- 12 %, p < 0.05), and raised HDL cholesterol (+ 7.5 %, p < 0.05) and apolipoprotein AI (+ 7.2 %, p < 0.05). Cerivastatin signficantly lowered apolipoprotein B in all LDL subfractions (- 21 to - 28 %, p < 0.05). Absolute changes were greatest in dense LDL and the change in dense LDL made the largest contribution to the change of total LDL. The change of dense LDL was highly correlated with baseline values. There was no consistent relationship between the effect of cerivastatin on triglycerides and the decrease of dense LDL.
Conclusions: The HMG CoA reductase inhibitor cerivastatin lowers total and LDL cholesterol and the concentration of dense LDL in patients with elevated fasting glucose, impaired glucose tolerance or type 2 diabetes.
Key words
Coronary heart disease - type 2 diabetes mellitus - impaired glucose tolerance - atherogenic lipoprotein phenotype - HMG-CoA reductase inhibitors
References
- 1 MRC/BH. F Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360 7-22
- 2 Austin M A, Bresolw J L, Hennekens C H, Buring J E, Willet W C, Krauss R M. Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988; 260 1917-1921
- 3 Austin M A, King M-C, Vranizan K M, Krauss R M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease. Circulation. 1990; 82 495-506
- 4 Auwerx J H, Marzetta C A, Hokanson J E, Brunzell J D. Large, buoyant LDL-like particles in hepatic lipase deficiency. Arterioscler Thromb. 1989; 9 319-325
- 5 Baumstark M W, Kreutz W, Berg A, Frey I, Keul J. Structure of human low-density lipoprotein subfractions, determined by X-ray small-angle scattering. Biochim Biophys Acta. 1990; 1037 48-57
- 6 Bredie S J, de Bruin T W, Demacker P N, Kastelein J J, Stalenhoef A F. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol. 1995; 75 348-353
- 7 Campos H, Genest J J, Blijlevens E, McNamara J, Jenner J L, Ordovas J M, Wilson P WF, Schaefer E J. Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb. 1992; 12 187-195
- 8 Campos H, Moye L A, Glasser S P, Stampfer M J, Sacks F M. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA. 2001; 286 1468-1474
- 9 Campos H, Roederer G O, Lussier-Cacan S, Davignon J, Krauss R M. Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease. Arterioscler Thromb Vasc Biol. 1995; 15 1043-1048
- 10 Campos H, Walsh B W, Judge H, Sacks F M. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab. 1997; 82 3955-3963
- 11 Chapman M J, Guerin M, Bruckert E. Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches. Eur Heart J. 1998; 19 (Suppl A) A24-A30
- 12 Cheung M C, Austin M A, Moulin P, Wolf A C, Cryer D, Knopp R H. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis. 1993; 102 107-119
- 13 Colhoun H M, Thomason M J, Mackness M I, Maton S M, Betteridge D J, Durrington P N, Hitman G A, Neil H A, Fuller J H. Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diabet Med. 2002; 19 201-211
- 14 Contacos C, Barter P J, Sullivan D R. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb. 1993; 13 1755-1762
- 15 Coresh J, Kwiterovich Jr P O, Smith H H, Bachorik P S. Association of plasma triglyceride concentration and LDL particle diameter, density, and chemical composition with premature coronary artery disease in men and women. J Lipid Res. 1993; 34 1687-1697
- 16 Crouse J R, Parks J S, Schey H M, Kahl F R. Studies of low density lipoprotein molecular weight in human beings with coronary artery disease. J Lipid Res. 1985; 26 566-574
- 17 de Graaf J, Demacker P N, Stalenhoef A F. The effect of simvastatin treatment on the low-density lipoprotein subfraction profile and composition in familial hypercholesterolaemia. Neth J Med. 1993; 43 254-261
- 18 Demant T, Carlson L A, Holmquist L, Karpe F, Nilsson-Ehle P, Packard C J, Shepherd J. Lipoprotein metabolism in hepatic lipase deficiency: studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein. J Lipid Res. 1988; 29 1603-1611
- 19 Forster L F, Stewart G, Bedford D, Stewart J P, Rogers E, Shepherd J, Packard C J, Caslake M J. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis. 2002; 164 129-145
- 20 Franceschini G, Cassinotti M, Vecchio G, Gianfranceschi G, Pazzucconi F, Murakami T, Sirtori M, AL DA, Sirtori C R. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb. 1994; 14 1569-1575
- 21 Frost R J, Otto C, Geiss H C, Schwandt P, Parhofer K G. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol. 2001; 87 44-48
- 22 Gardner C D, Fortmann S P, Krauss R M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996; 276 875-881
- 23 Gaw A, Packard C J, Murray E F, Lindsay G M, Griffin B A, Caslake M J, Vallance B D, Lorimer A R, Shepherd J. Effects of simvastatin on apo B metabolism and LDL subfraction distribution. Arterioscler Thromb. 1993; 13 170-189
- 24 Geiss H C, Otto C, Schwandt P, Parhofer K G. Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. Metabolism. 2001; 50 983-988
- 25 Geiss H C, Schwandt P, Parhofer K G. Influence of simvastatin on LDL-subtypes in patients with heterozygous familial hypercholesterolemia and in patients with diabetes mellitus and mixed hyperlipoproteinemia. Exp Clin Endocrinol Diabetes. 2002; 110 182-187
- 26 Goldberg R B, Mellies M J, Sacks F M, Moye L A, Howard B V, Howard W J, Davis B R, Cole T G, Pfeffer M A, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998; 98 2513-2519
- 27 Gray R S, Robbins D C, Wang W, Yeh J L, Fabsitz R R, Cowan L D, Welty T K, Lee E T, Krauss R M, Howard B V. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arterioscler Thromb Vasc Biol. 1997; 17 2713-2720
- 28 Griffin B A, Freeman D J, Tait G W, Thomson J, Caslake M J, Packard C J, Shepherd J. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 1994; 106 241-253
- 29 Guerin M, Dolphin P J, Talussot C, Gardette J, Berthezene F, Chapman M J. Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 1995; 15 1359-1368
- 30 Hoogerbrugge N, Jansen H. Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. Atherosclerosis. 1999; 146 167-174
- 31 Kontopoulos A G, Athyros V G, Papageorgiou A A, Hatzikonstandinou H A, Mayroudi M C, Boudoulas H. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. Coron Artery Dis. 1996; 7 843-850
- 32 Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais G R, Lupien P J, Despres J P. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997; 95 69-75
-
33 Lindgren F T.
Preparative ultracentrifuge labaratory procedures and suggestions for lipoprotein analysis. Perkins EG Analysis of Lipids and Lipoproteins. Champaign, IL; Am Oil Chem Soc 1975: 204-224 - 34 Mack W J, Krauss R M, Hodis H N. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol. 1996; 16 697-704
- 35 März W, Grützmacher P, Paul D, Schoeppe W, Groß W. Effects of Lovastatin (20 to 80 mg daily) on lipoprotein fractions in patients with severe primary hypercholesterolemia. Clin Pharmacol Ther Toxicol. 1994; 32 92-97
- 36 März W, Scharnagl H, Abletshauser C, Hoffmann M M, Berg A, Keul J, Wieland H, Baumstark M W. Inhibition of HMG-CoA reductase with fluvastatin lowers atherogenic, dense low density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype. Circulation. 2001; 103 1942-1948
- 37 McNamara J R, Jenne J L, Ji Z, Wilson P WF, Schaefer E J. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb Vasc Biol. 1992; 12 1284-1290
- 38 Mykkanen L, Kuusisto J, Haffner S M, Laakso M, Austin M A. LDL size and risk of coronary heart disease in elderly men and women. Arterioscler Thromb Vasc Biol. 1999; 19 2742-2748
- 39 Nigon F, Lesnik P, Rouis M, Chapman M J. Discrete subspecies of human low density lipoproteins are heterogenous in their interaction with the cellular LDL receptor. J Lipid Res. 1991; 32 1741-1753
- 40 Packard C J, Shepherd J. Lipoprotein heterogeneity and apolipoprotein B metabolism. Arterioscler Thromb Vasc Biol. 1997; 17 3542-3556
- 41 Patsch J R, Prasad S, Gotto A M, Patsch W. High density lipoprotein2. Relationship of the plasma levels of this lipoprotein species to its composition, to the magnitude of postprandial lipemia, and to the activities of lipoprotein lipase and hepatic lipase. J Clin Invest. 1987; 80 341-347
- 42 Plosker G L, Dunn C I, Figgitt D P. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia. Drugs. 2000; 60 1179-1206
- 43 Pontrelli L, Parris W, Adeli K, Cheung R C. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism. 2002; 51 334-342
- 44 Pyorala K, Pedersen T R, Kjekshus J, Faergeman O, Olsson A G, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4 S). Diabetes Care. 1997; 20 614-620
- 45 Ruotolo G, Tettamanti C, Garancini M P, Ragogna F, Derosa G, Nardecchia L, Parlato F, Pozza G. Smaller, denser LDL particles are not a risk factor for cardiovascular disease in healthy nonagenarian women of the Cremona Population Study. Atherosclerosis. 1998; 140 65-70
- 46 Sacks F M, Alaupovic P, Moye L A. Effect of pravastatin on apolipoproteins B and C-III in very-low-density lipoproteins and low-density lipoproteins. Am J Cardiol. 2002; 90 165-167
- 47 Scharnagl H, Schinker R, Gierens H, Nauck M, Wieland H, Marz W. Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001; 62 1545-1555
- 48 Stampfer M J, Krauss R M, Ma J, Blanche P J, Holl L G, Sacks F M, Hennekens C H. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 1996; 276 882-888
- 49 Superko H R, Krauss R M. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis. 1992; 95 69-76
- 50 Superko H R, Krauss R M, Di Ricco C. Effect of fluvastatin on low-density lipoprotein peak particle diameter. Am J Cardiol. 1997; 80 78-81
- 51 Tan C E, Forster L, Caslake M J, Bedford D, Watson T DG, McConnell M, Packard C J, Shepherd J. Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfractions in normolipidemic men and women. Arterioscler Thromb Vasc Biol. 1995; 15 1839-1848
- 52 Tilly-Kiesi M. The effect of lovastatin on low-density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia. Metabolism. 1991; 40 623-628
- 53 Tornvall P, Bavenholm P, Landou C, de Faire U, Hamsten A. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation. 1993; 88 2180-2189
- 54 Tornvall P, Karpe F, Carlson L A, Hamsten A. Relationships of low density lipoprotein subfractions to angiographically defined coronary artery disease in young survivors of myocardial infarction. Atherosclerosis. 1991; 90 67-80
- 55 Turner R C, Millns H, Neil H A, Stratton I M, Manley S E, Matthews D R, Holman R R. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). Br Med J. 1998; 316 823-828
- 56 Wahi S, Gatzka C D, Sherrard B, Simpson H, Collins V, Dowse G, Zimmet P, Jennings G, Dart A M. Risk factors for coronary heart disease in a population with a high prevalence of obesity and diabetes: a case-control study of the Polynesian population of Western Samoa. J Cardiovasc Risk. 1997; 4 173-178
- 57 Wanner C, Krane V, Ruf G, Marz W, Ritz E. Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators. Kidney Int Suppl. 1999; 71 S222-226
- 58 Watson T DG, Caslake M J, Freeman D J, Griffin B A, Hinnie J, Packard C J, Shepherd J. Determinants of low-density lipoprotein subfraction distribution and concentrations in young normolipidemic subjects. Atherosclerosis. 1994; 107 45-54
- 59 Watts G F, Mandalia S, Brunt J N, Slavin B M, Coltart D J, Lewis B. Independent associations between plasma lipoprotein subfraction levels and the course of coronary artery disease in the St. Thomas' Atherosclerosis Regression Study (STARS). Metabolism. 1993; 42 1461-1467
- 60 Winkler K, Abletshauser C, Hoffmann M M, Friedrich I, Baumstark M W, Wieland H, Marz W. Effect of fluvastatin slow-release on low density lipoprotein (LDL) subfractions in patients with type 2 diabetes mellitus: baseline LDL profile determines specific mode of action. J Clin Endocrinol Metab. 2002; 87 5485-5490
- 61 Yuan J, Tsai M Y, Hegland J, Hunninghake D B. Effects of fluvastatin (XU 62 - 320), an HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis. 1991; 87 147-157
- 62 Zambon A, Austin M A, Brown B G, Hokanson J E, Brunzell J D. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arterioscler Thromb. 1993; 13 147-153
- 63 Zambon S, Cortella A, Sartore G, Baldo-Enzi G, Manzato E, Crepaldi G. Pravastatin treatment in combined hyperlipidaemia. Effect on plasma lipoprotein levels and size. Eur J Clin Pharmacol. 1994; 46 221-224
- 64 Zhao S P, Hollaar L, van't Hoft F M, Smelt A HM, Leuven J AG, van der Laarse A. Effect of simvastatin on the apparent size of LDL particles in patients with type IIb hyperlipoproteinemia. Clin Chim Acta. 1991; 203 109-118
Hubert Scharnagl
Clinical Institute of Medical and Chemical Laboratory Diagnostics
Karl-Franzens-University Graz
Auenbruggerplatz 15
8036 Graz
Austria
Phone: + 433163857816
Fax: + 43 31 63 85 34 30
Email: hubert.scharnagl@klinikum-graz.at